All Articles

Patients with advanced KRAS^G12C harboring NSCLC maintained quality of life and physical functioning with tolerable side effects while being treated with sotorasib.

Targeted Therapy and Immunotherapy May Improve NSCLC Survival Rates

Lung Cancer

Web Exclusives

Data indicate a steady improvement over the past decade in NSCLC survival rates due to immunotherapy and targeted therapy.

Rapidly Evolving Landscape for Biomarker Testing in NSCLC Prompts Updated European Recommendations

Lung Cancer

Web Exclusives

A recent review article provided best practices for biomarker testing and recommendations for the diagnosis and management of patients with advanced NSCLC.

Study Analyzes Mortality Differences Between Black and White Patients with Stage III NSCLC

Lung Cancer

Web Exclusives

Treatment timing and type at time of diagnosis of stage III NSCLC influences patients’ overall survival, with gender and race differences also influencing therapy.

FDA Grants Accelerated Approval of Sotorasib for Patients with NSCLC-Harboring KRAS Mutations

Lung Cancer

Web Exclusives

Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant accelerated approval for sotorasib for patients with KRAS^G12C-mutated NSCLC.

Best Practices in GU Navigation

Combination Therapy in Renal-Cell Carcinoma and Quality of Life

By Megan Price, MSN, APRN, FNP-C; Virginia Seery, CRNP, MSN; Laura Wood, RN, MSN, OCN

Interview with the Innovators

Video Library

Combination therapy continues to evolve in the renal-cell carcinoma space. However, along with improved efficacy come the tests of adverse events and their impact on quality of life. Please join Laura Wood, RN, MSN, OCN, Virginia Seery, MSN, RN, ANP-BC, AOCNP, and Megan Price, MSN, APRN, FNP-C, as they discuss the ways in which drug combinations improve outcomes but also present their own set of challenges for patients’ quality of life.

AONN+ Navigation Metrics Toolkit: Support in the Quest to Capture Data

By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

Letters from Lillie

June 2021 Vol 12, No 6

As a member of AONN+, you have heard AONN+ leadership speak to the importance of program metrics. While it seems rather obvious to say that navigators should measure their impact on their respective cancer programs, there are still many questions around the best approach to implement metrics.

Call Back: Using the Phone to Promote Adherence to Oral Antineoplastic Agents

By Rachel M. Akerley, MSN, RN, OCN; Cherry Karl, PhD, CNE

Original Research

June 2021 Vol 12, No 6

Have you overlooked this simple and effective tool in your practice?

IWTI 2021

The Navigation Metrics Toolkit: Measuring the Effectiveness of Your Navigation Program

Interview with the Innovators

June 2021 Vol 12, No 6

Not sure how to capture the data you need to assess your navigation program?

We’ve got you covered with our AONN+ Metrics Toolkit.

IWTI 2021